Coloplast High Valuation Is Untenable, Nordea Says, Reiterating Sell

• (PLX AI) - Coloplast has a valuation close to all-time highs, which is untenable, according to Nordea analysts, who reiterated a sell recommendation on the stock.
• • Coloplast likely will have a soft first half of the new fiscal year, with slowing growth and rising input costs, Nordea said
• • The acquisition of Atos Medical is a good strategic fit, but more than fully reflected in the recent share price jump: Nordea
• • Price target raised to DKK 1,033 from DKK 960; recommendation remains sell
• • Coloplast closed at DKK 1,170 yesterday